Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Produits et services

Pharmaceutical preparations for the treatment of infectious diseases; medicinal preparations for the treatment and prevention of cancer and infectious diseases, including coronavirus, for administration as a vaccine; pharmaceutical preparations for the prevention of infectious diseases, including coronavirus, for administration as a vaccine; pharmaceutical preparations for the treatment of cancer, including coronavirus, for administration as a vaccine; pharmaceutical preparations for the prevention of cancer, including coronavirus, for administration as a vaccine; biological preparations for the prevention and treatment of cancer and infectious diseases, including coronavirus, for administration as a vaccine.

Abrégé

Provided herein are multi-chain chimeric polypeptides and use thereof in reducing neuroinflammation in a subject.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/20 - Interleukines
• A61P 25/16 - Antiparkinsoniens

Abrégé

Provided herein are compositions of NK-92™ cells that express a combination of PD-L1 CAR, CD16 and IL2, and the method of using these cells to to reduce tumor cells and cells in tumor microenvironment (e.g., MDSCs or TAMs) and treat cancer.

Classes IPC  ?

• C07K 14/735 - Récepteurs Fc
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/30 - Immunothérapie cellulaire caractérisée par l’expression recombinante de molécules spécifiques dans les cellules du système immunitaire
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/35 - Cytokines
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• C07K 14/54 - Interleukines [IL]
• C07K 14/55 - IL-2
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

Disclosed herein are methods, compositions and kits for treating non-small cell lung carcinoma (NSCLC) in a human subject, wherein the subject has been previously treated with an immune checkpoint inhibitor, the method comprising administering either an interleukin-15 (IL-15) protein or fusion protein derivative thereof, or an interleukin-15:interleukin-15 receptor subunit alpha (IL-15:IL-15Rα) protein or fusion protein derivative thereof, and a PD-1 inhibitor antibody and a taxane. Further disclosed is a treatment regime for administering either the IL-15 protein or fusion protein derivative thereof, or the IL-15:IL-15Rα protein or fusion protein derivative thereof in combination with administering a PD-1 inhibitor antibody and a taxane.

Classes IPC  ?

• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/20 - Interleukines
• A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire
• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

Disclosed herein are methods, compositions and kits for treating non-small cell lung carcinoma (NSCLC) in a human subject, wherein the subject has been previously treated with an immune checkpoint inhibitor, the method comprising administering either an interleukin-15 (IL-15) protein or fusion protein derivative thereof, or an interleukin-15:interleukin-15 receptor subunit alpha (IL-15:IL-15Rα) protein or fusion protein derivative thereof, and a PD-1 inhibitor antibody and a taxane. Further disclosed is a treatment regime for administering either the IL-15 protein or fusion protein derivative thereof, or the IL-15:IL-15Rα protein or fusion protein derivative thereof in combination with administering a PD-1 inhibitor antibody and a taxane.

Classes IPC  ?

• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
• A61K 38/00 - Préparations médicinales contenant des peptides
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• C07K 14/54 - Interleukines [IL]
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Produits et services

Recruitment advertisement services, namely, posting of clinical trial notices for the purpose of recruiting patients for participation in clinical trials for the testing of drugs Providing medical and scientific research information in the field of pharmaceuticals and clinical trials

Produits et services

Downloadable chatbot software using artificial intelligence (AI) for the management, coordination, and execution of clinical trials in the life sciences Providing temporary use of online non-downloadable chatbot software using artificial intelligence (AI) for the management, coordination, and execution of clinical trials in the life sciences

Abrégé

Disclosed herein are compositions and methods for treating solid tumors with yeast-based formulations.

Classes IPC  ?

• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 35/04 - Agents anticancéreux spécifiques pour le traitement des métastases
• C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

Methods and compositions are provided for generating cytokine-induced memory-like (CIML) phenotypes in NK-92-derived cell lines including activated NK (aNK) and PD-L1 chimeric antigen receptor NK (PD-L1 t-haNK) cells. Brief exposure of the cells to interleukin-12, interleukin-18, and the interleukin-15 (or interleukin-15 superagonist N-803) induces durable interferon-gamma expression and a memory recall response that persists for at least a week after stimulation. The disclosure includes methods for manufacturing, irradiating, and cryopreserving CIML aNK and CIML t-haNK cell products that provide a standardized off-the-shelf therapy for the targeted treatment of cancers, including tumors that are initially resistant to NK-cell cytotoxicity.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/00 - Agents anticancéreux
• C07K 14/54 - Interleukines [IL]
• C07K 14/735 - Récepteurs Fc
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

Methods and compositions are provided for generating cytokine-induced memory-like (CIML) phenotypes in NK-92-derived cell lines including activated NK (aNK) and PD-L1 chimeric antigen receptor NK (PD-L1 t-haNK) cells. Brief exposure of the cells to interleukin-12, interleukin-18, and the interleukin-15 (or interleukin-15 superagonist N-803) induces durable interferon-gamma expression and a memory recall response that persists for at least a week after stimulation. The disclosure includes methods for manufacturing, irradiating, and cryopreserving CIML aNK and CIML t-haNK cell products that provide a standardized off-the-shelf therapy for the targeted treatment of cancers, including tumors that are initially resistant to NK-cell cytotoxicity.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61P 35/00 - Agents anticancéreux
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Produits et services

(1) Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Produits et services

(1) Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Produits et services

(1) Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Abrégé

Provided herein are multi-chain chimeric polypeptides and use thereof in modulating circadian clock gene expression in a subject.

Classes IPC  ?

• A61K 38/36 - Facteurs de coagulation sanguine ou de fibrinolyse
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 38/20 - Interleukines

Abrégé

Provided herein are single-chain chimeric polypeptides that include: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a second target-binding domain. Also provided here are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.

Classes IPC  ?

• C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61P 3/10 - Médicaments pour le traitement des troubles du métabolisme de l'homéostase du glucose de l'hyperglycémie, p. ex. antidiabétiques
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

Provided herein are modified NK-92 cells comprising a nucleic acid encoding C-C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cells further comprise a nucleic acid encoding C-C motif ligand 21 (CCL21), a nucleic acid encoding C-C motif ligand 19 (CCL19) or a combination thereof. Also provided are compositions and kits comprising the modified NK-92 cells. Provided are methods of making the modified cells and methods of treating cancer using the cells.

Classes IPC  ?

• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer
• C07K 14/52 - CytokinesLymphokinesInterférons
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

Provided herein are multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases.

Classes IPC  ?

• A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
• A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
• A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
• A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p. ex. protecteurs hépatiques, cholagogues, cholélitholytiques

Abrégé

Systems and methods are presented that provide for improved NK cell function. In preferred aspects, NK-92 cells express recombinant er/LSP-IL-15 to so render the NK-92 cells independent of exogenous cytokines and to provide extracellular immune stimulation.

Classes IPC  ?

• C07K 14/54 - Interleukines [IL]
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/30 - Immunothérapie cellulaire caractérisée par l’expression recombinante de molécules spécifiques dans les cellules du système immunitaire
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/35 - Cytokines
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/00 - Agents anticancéreux
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Produits et services

(1) Pharmaceutical preparations for the treatment of infectious diseases; medicinal preparations for the treatment and prevention of cancer and infectious diseases, including coronavirus, for administration as a vaccine; pharmaceutical preparations for the prevention of infectious diseases, including coronavirus, for administration as a vaccine; pharmaceutical preparations for the treatment of cancer, including coronavirus, for administration as a vaccine; pharmaceutical preparations for the prevention of cancer, including coronavirus, for administration as a vaccine; biological preparations for the prevention and treatment of cancer and infectious diseases, including coronavirus, for administration as a vaccine.

Abrégé

A method for the production of proteins used in the in vitro transcription (IVT) of messenger RNA (mRNA), wherein the proteins are evaluated for purity and efficacy by the efficiency with which mRNA synthetically derived therefrom, subsequently transfects cells and produces encoded proteins.

Classes IPC  ?

• C12P 19/34 - Polynucléotides, p. ex. acides nucléiques, oligoribonucléotides
• C12N 9/12 - Transférases (2.) transférant des groupes contenant du phosphore, p. ex. kinases (2.7)

Abrégé

Provided herein are methods and compositions for the removal and isolation of target blood cells from a whole blood sample using bifunctional fusion proteins. The fusion proteins may include a first binding domain that is specific for a red blood cell (RBC) surface antigen, a cleavable or stable linker, and a second binding domain that is specific for a cell-surface expressed antigen of a target blood cell. The methods may involve adding the fusion protein to the whole blood, followed by centrifugation to produce a pellet comprising RBCs bound to target blood cells. The target blood cells may include non-RBC cell types such as antigen-presenting cells, which may express an MHC-presented peptide derived from an infectious agent or cancer-associated antigen. The target blood cells may be further separated from RBCs by lysing or cleaving the linker. Also provided are compositions, kits, and methods for identifying infected or cancerous white blood cells using MHC-targeted binding domains.

Classes IPC  ?

• G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus

Abrégé

Provided herein are methods and compositions for the removal and isolation of target blood cells from a whole blood sample using bifunctional fusion proteins. The fusion proteins may include a first binding domain that is specific for a red blood cell (RBC) surface antigen, a cleavable or stable linker, and a second binding domain that is specific for a cell-surface expressed antigen of a target blood cell. The methods may involve adding the fusion protein to the whole blood, followed by centrifugation to produce a pellet comprising RBCs bound to target blood cells. The target blood cells may include non-RBC cell types such as antigen-presenting cells, which may express an MHC-presented peptide derived from an infectious agent or cancer-associated antigen. The target blood cells may be further separated from RBCs by lysing or cleaving the linker. Also provided are compositions, kits, and methods for identifying infected or cancerous white blood cells using MHC-targeted binding domains.

Classes IPC  ?

• B01D 21/01 - Séparation par sédimentation de particules solides en suspension dans des liquides en utilisant des agents de floculation
• B01D 21/26 - Séparation du sédiment avec emploi de la force centrifuge
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 9/64 - Protéinases provenant de tissu animal, p. ex. rennine

Abrégé

A system and method are described. An illustrative method includes receiving a digital dataset representing waveform data comprising the waveform, windowing the digital dataset such that no more than two periods of the waveform exist within a windowed version of the digital dataset, providing the windowed version of the dataset to a trained machine learning model, receiving an output signal from the trained machine learning model, where the output signal is generated by the machine learning model in response to the trained machine learning model processing the windowed version of the dataset, generating the heatmap with the output signal received from the trained machine learning model, and causing a device to take action based on the heatmap.

Classes IPC  ?

• G06T 11/20 - Traçage à partir d'éléments de base, p. ex. de lignes ou de cercles

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; Biological preparations for the prevention and treatment of cancer and infectious diseases; Pharmaceutical preparations for the treatment of cancer and infectious diseases; Pharmaceutical preparations for the prevention of cancer and infectious diseases; Vaccines

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; Biological preparations for the prevention and treatment of cancer and infectious diseases; Pharmaceutical preparations for the treatment of cancer and infectious diseases; Pharmaceutical preparations for the prevention of cancer and infectious diseases; Vaccines

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Abrégé

Provided herein are populations of modified NK-92 cells, compositions and kits comprising the cells, and methods of making and using the populations of cells.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/42 - Antigènes associés au cancer
• A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiquesThérapie génique
• C07K 14/55 - IL-2
• C07K 14/735 - Récepteurs Fc
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales

Abrégé

Methods and systems are disclosed for manipulating inert materials and biomaterials, including cell cultures, to efficiently form effective cell beds while preventing excess flow through of cells to permeate waste during bioprocessing. Gentle centrifugation concentrates a large volume of cells produced from bioreactors into the desired concentrated volume and cell density. When cells pass through the centrifuge, the majority fraction of cells are retained in the centrifuge disposable chamber pods as a cell bed. A recirculation loop redirects the remaining minority fraction of cells back to the cell bag instead of proceeding to waste. This prevents initial cell loss during cell bed formation in the chamber pods, increases overall cell yields at harvest, and conserves materials, for example. Growing and harvesting natural killer cells, in particular, increased yields by over 30% when the recirculation loop was employed.

Classes IPC  ?

• C12M 1/12 - Appareillage pour l'enzymologie ou la microbiologie avec des moyens de stérilisation, filtration ou dialyse
• C12M 1/00 - Appareillage pour l'enzymologie ou la microbiologie
• C12M 1/26 - Inoculateur ou échantillonneur
• C12M 1/34 - Mesure ou test par des moyens de mesure ou de détection des conditions du milieu, p. ex. par des compteurs de colonies
• C12M 3/04 - Appareillage pour la culture de tissus, de cellules humaines, animales ou végétales, ou de virus comportant des moyens fournissant des couches minces
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; Pharmaceutical preparations for the treatment of of infectious diseases; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the prevention of cancer; Biological preparations for the prevention and treatment of cancer and infectious diseases; Vaccines Downloadable digital publications, namely, downloadable brochures, booklets, and journal articles in the field of cancer and infectious diseases therapy Printed publications, namely, brochures, booklets, and journal articles in the field of cancer and infectious diseases therapy Providing information about medical and scientific research via a website; Medical and scientific research in the field of cancer treatment; Product development in the field of cancer and infectious diseases therapy Providing medical information via a website

Produits et services

Cryopreservation services Medical services relating to the removal, treatment and processing of human cells

Produits et services

(1) Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Abrégé

Methods and compositions are provided herein whereby a patient with cancer is administered a treatment comprising NK cells in order to induce expression of MHC-I in a tumor, and wherein subsequent treatment with T cells effectively targets tumor associated antigens and neoepitopes presented by newly expressed MHC-I in said tumor cells.

Classes IPC  ?

• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 31/20 - Acides carboxyliques, p. ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p. ex. acides stéarique, palmitique ou arachidique
• A61K 31/502 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes carbocycliques, p. ex. cinnoline, phtalazine
• A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
• A61K 31/7068 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique
• A61K 31/7072 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p. ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées ayant des groupes oxo liés directement au cycle pyrimidine, p. ex. cytidine, acide cytidylique ayant deux groupes oxo liés directement au cycle pyrimidine, p. ex. uridine, acide uridylique, thymidine, zidovudine
• A61K 31/7105 - Acides ribonucléiques naturels, c.-à-d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 38/20 - Interleukines
• A61K 38/21 - Interférons
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/32 - Récepteurs des lymphocytes T [TCR]
• A61K 40/35 - Cytokines
• A61K 40/42 - Antigènes associés au cancer
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• A61P 35/00 - Agents anticancéreux
• C07K 16/00 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux
• G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides

Abrégé

Provided herein are compositions and methods related to potent cytotoxic M-CENK cells from CD3/CD14 depleted apheresis products.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/42 - Antigènes associés au cancer
• A61P 35/00 - Agents anticancéreux
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 5/00 - Cellules non différenciées humaines, animales ou végétales, p. ex. lignées cellulairesTissusLeur culture ou conservationMilieux de culture à cet effet
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Abrégé

Provided herein are compositions and methods related to potent cytotoxic M-CENK cells from CD3/CD14 depleted apheresis products.

Classes IPC  ?

• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• A61K 35/00 - Préparations médicinales contenant des substances ou leurs produits de réaction de constitution non déterminée

Abrégé

Provided herein are compositions and methods for detecting migration of effector cells towards a target cell, and cytotoxicity of the migrated effector cells against the target cells. The effector cells are modified to express a homing or migratory receptor, and the target cells are modified to express the cognate ligand. The methods can be carried out in a Boyden chamber or tranwells with a porous membrane between the wells. The membrane can be coated with an extracellular matrix component to simulate a solid tumor environment.

Classes IPC  ?

• G01N 33/50 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer

Abrégé

Anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and chimeric antigen receptors (CARs) are provided herein. Also provided are polynucleotides encoded the anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and CARs. The anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and CARs are useful for the prevention and/or treatment of cancer, such as multiple myeloma. Also provided is a combination therapy including administration of the anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and CARs with an IL-16 or an IL-15 agonist.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 40/11 - Lymphocytes T, p. ex. lymphocytes infiltrant les tumeurs [TIL] ou lymphocytes T régulateurs [Treg]Cellules tueuses activées par les lymphokines [LAK]
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer
• C07K 14/54 - Interleukines [IL]
• C07K 14/715 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des cytokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des lymphokinesRécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire pour des interférons

Abrégé

Anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and chimeric antigen receptors (CARs) are provided herein. Also provided are polynucleotides encoded the anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and CARs. The anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and CARs are useful for the prevention and/or treatment of cancer, such as multiple myeloma. Also provided is a combination therapy including administration of the anti-SLAMF7 Fab fragments, antibodies, biparatopic antibodies, and CARs with an IL-16 or an IL-15 agonist.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 38/20 - Interleukines
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61P 35/00 - Agents anticancéreux
• C07K 14/54 - Interleukines [IL]

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention and treatment of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Printed publications, namely, brochures, booklets, and teaching materials, in the field of diagnosis and prognosis of cancer and infectious diseases Providing medical information via a website

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; biological preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; biological preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; biological preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; vaccines.

Produits et services

Printed publications, namely, brochures, booklets, and teaching materials, in the field of diagnosis and prognosis of cancer and infectious diseases Providing medical information via a website

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the prevention of cancer; Biological preparations for the prevention and treatment of cancer and infectious diseases; Vaccines

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the prevention of cancer; Biological preparations for the prevention and treatment of cancer and infectious diseases; Vaccines

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the prevention of cancer; Biological preparations for the prevention and treatment of cancer and infectious diseases; Vaccines

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the prevention of infectious diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for the prevention of cancer; Biological preparations for the prevention and treatment of cancer and infectious diseases; Vaccines

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Pharmaceutical preparations for the treatment of infectious diseases; Medicinal preparations for the treatment and prevention of cancer and infectious diseases in the nature of coronavirus for administration as a vaccine; Pharmaceutical preparations for the prevention of infectious diseases in the nature of coronavirus for administration as a vaccine; Pharmaceutical preparations for the treatment of cancer and coronavirus for administration as a vaccine; Pharmaceutical preparations for the prevention of cancer and coronavirus for administration as a vaccine; Biological preparations for the prevention and treatment of cancer and infectious diseases in the nature of coronavirus for administration as a vaccine

Produits et services

(1) Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention and treatment of lymphopenia, cancer, and infectious diseases; vaccines.

Abrégé

Provided herein are multi-chain chimeric polypeptides and use thereof in treating bronchopulmonary dysplasia in a subject.

Classes IPC  ?

• A61K 38/18 - Facteurs de croissanceRégulateurs de croissance
• A61K 38/20 - Interleukines
• A61K 38/36 - Facteurs de coagulation sanguine ou de fibrinolyse
• A61P 11/00 - Médicaments pour le traitement des troubles du système respiratoire

Produits et services

(1) Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Produits et services

(1) Medicinal preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; biological preparations for the prevention and treatment of cancer and infectious diseases; vaccines.

Produits et services

Cells for scientific, laboratory or medical research; diagnostic preparations other than for medical or veterinary purposes; assays for research purposes. Diagnostic preparations for medical use. Medical and scientific research in the field of cancer treatment and diagnosis; product development; scientific research; medical research; pharmaceutical research and development; veterinary research.

Produits et services

Cells for scientific, laboratory or medical research; diagnostic preparations other than for medical or veterinary purposes; assays for research purposes. Diagnostic preparations for medical use. Medical and scientific research in the field of cancer treatment and diagnosis; product development; scientific research; medical research; pharmaceutical research and development; veterinary research.

Produits et services

Cells for scientific, laboratory or medical research; diagnostic preparations other than for medical or veterinary purposes; assays for research purposes. Diagnostic preparations for medical use. Medical and scientific research in the field of cancer treatment and diagnosis; product development; scientific research; medical research; pharmaceutical research and development; veterinary research.

Abrégé

An autonomous tracking system receives a request to administer a patient-specific therapeutic comprising a scanned identifier associated with a labeled dual chamber device (DCD) including a first chamber having one or more lyophilized components, a second chamber having a reconstitution buffer, and a locking mechanism for controlling access to the DCD chambers. A tracking engine queries an administration database based on the scanned identifier to find a notarized ledger associated with the DCD and retrieves a blockchain entry comprising a first distributed ledger transaction identifying the one or more lyophilized components and a digital token associated with an owner of the labeled DCD. After the owner is authenticated, a second distributed transaction is created identifying the one or more lyophilized components as being authorized for administration to the patient. In response, autonomous access to the one or more lyophilized components unlocks the locking mechanism to administer the medication.

Classes IPC  ?

• G16H 20/13 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients delivrés par des distributeurs
• G07C 9/00 - Enregistrement de l’entrée ou de la sortie d'une entité isolée

Abrégé

This invention is directed to treatment of a subject having or suspected of having a cancer comprising administering to the subject a monoclonal antibody and NK-92 expressing Fc receptor.

Classes IPC  ?

• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
• A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/42 - Antigènes associés au cancer
• C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK

Produits et services

Cells for scientific, laboratory or medical research; diagnostic preparations other than for medical or veterinary purposes; assays for research purposes. Diagnostic preparations for medical use. Medical and scientific research in the field of cancer treatment and diagnosis; product development; scientific research; medical research; pharmaceutical research and development; veterinary research.

Abrégé

Disclosed herein are mannan nanogels as a novel vaccine delivery platform as well as a novel method of making a self-assembling mannan nanogel for in vivo delivery of therapeutic agents.

Classes IPC  ?

• A61K 9/06 - OnguentsExcipients pour ceux-ci
• A61K 38/06 - Tripeptides
• A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
• A61K 47/36 - PolysaccharidesLeurs dérivés, p. ex. gommes, amidon, alginate, dextrine, acide hyaluronique, chitosane, inuline, agar-agar ou pectine
• C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
• C12N 15/87 - Introduction de matériel génétique étranger utilisant des procédés non prévus ailleurs, p. ex. co-transformation

Produits et services

(1) Medicinal preparations for the treatment and prevention of cancer and infectious diseases; biological preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; vaccines.

Produits et services

(1) Medicinal preparations for the treatment and prevention of cancer and infectious diseases; biological preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; vaccines.

Produits et services

(1) Medicinal preparations for the treatment and prevention of cancer and infectious diseases; biological preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Pharmaceutical preparations for the treatment of infectious diseases; Medicinal preparations for the treatment and prevention of cancer and infectious diseases, in the nature of coronavirus, for administration as a vaccine; Pharmaceutical preparations for the prevention of infectious diseases, in the nature of coronavirus, for administration as a vaccine; Pharmaceutical preparations for the treatment of cancer and coronavirus, for administration as a vaccine; Pharmaceutical preparations for the prevention of cancer and coronavirus, for administration as a vaccine; Biological preparations for the prevention and treatment of cancer and infectious diseases in the nature of coronavirus, for administration as a vaccine

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Pharmaceutical preparations for the treatment and prevention of lymphopenia; pharmaceutical preparations for use in stimulating lymphocyte production; pharmaceutical preparations for maintenance of lymphocyte counts; pharmaceutical preparations for the treatment and prevention of immunosuppressive side effects of chemotherapy, radiotherapy, and pathogenic infections.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Abrégé

An NK cell lysate is provided herein that includes a salt solution, a cytotoxic protein, and IL-16 endogenously produced by NK cells. Also provided is a composition including the NK cell lysate and optionally NK cell exosomes. A method of preparing the NK cell lysate and composition is provided herein, including lysing the NK cells to produce a lysate and removing intact NK cells, NK cell debris, and NK cell genomic DNA from the lysate, as well as a method for generating IL-16 from NK cells. Also provided herein are methods for stimulating an immune response, preventing, reducing the occurrence of, and/or treating an infection; preventing, reducing the occurrence of, and/or treating cancer; and initiating, enhancing, or prolonging an anti-tumor response. Also provided is a combination therapy including administering the NK cell lysate or composition and a therapeutically active agent, and a vaccine including the NK cell lysate or composition.

Classes IPC  ?

• A61K 35/17 - LymphocytesLymphocytes BLymphocytes TCellules tueuses naturellesLymphocytes activés par un interféron ou une cytokine
• A61P 35/00 - Agents anticancéreux
• A61K 40/13 - Lymphocytes B
• C07K 14/54 - Interleukines [IL]

Produits et services

Medicinal preparations; biological preparations; pharmaceutical preparations; vaccines; immune boosters being medicinal preparations and pharmaceutical preparations; all of the aforementioned containing any of messenger RNA, an adenovirus vector, or a yeast vector; and all of the aforementioned for use in the treatment and/or prevention of cancer and infectious diseases.

Produits et services

Pharmaceutical preparations for the treatment and prevention of lymphopenia; pharmaceutical preparations for use in stimulating lymphocyte production; pharmaceutical preparations for maintenance of lymphocyte counts; pharmaceutical preparations for the treatment and prevention of immunosuppressive side effects of chemotherapy, radiotherapy, and pathogenic infections.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

(1) Medicinal preparations for the treatment and prevention of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the treatment of lymphopenia, cancer, and infectious diseases; pharmaceutical preparations for the prevention of lymphopenia, cancer, and infectious diseases; biological preparations for the treatment of lymphopenia, cancer, and infectious diseases; biological preparations for the prevention of lymphopenia, cancer, and infectious diseases; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; biological preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; vaccines.

Produits et services

Medicinal preparations for the treatment and prevention of cancer and infectious diseases; biological preparations for the treatment and prevention of cancer and infectious diseases; pharmaceutical preparations for the treatment of infectious diseases; pharmaceutical preparations for the prevention of infectious diseases; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations for the prevention of cancer; vaccines.

Abrégé

Disclosed herein are methods of treating one or more symptoms associated with a viral infection in a patient exposed to a virus. wherein the virus is no longer detectable in the patient, and wherein the symptoms develop or persist after clearance of the virus. The methods comprise administering to the patient an effective amount of a pharmaceutical composition comprising interleukin-15 (IL-15) or an IL-15 agonist derivative thereof.

Classes IPC  ?

• A61K 38/20 - Interleukines
• A61P 31/14 - Antiviraux pour le traitement des virus ARN

Abrégé

Disclosed herein are methods of treating one or more symptoms associated with a viral infection in a patient exposed to a virus. wherein the virus is no longer detectable in the patient, and wherein the symptoms develop or persist after clearance of the virus. The methods comprise administering to the patient an effective amount of a pharmaceutical composition comprising interleukin-15 (IL-15) or an IL-15 agonist derivative thereof.

Classes IPC  ?

• A61K 38/20 - Interleukines
• A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
• A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
• A61K 39/215 - Coronaviridae, p. ex. virus de la bronchite infectieuse aviaire
• A61P 31/14 - Antiviraux pour le traitement des virus ARN
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire

Abrégé

Disclosed herein are recombinant nucleic acids, comprising a 5′ untranslated (5′-UTR) sequence portion, a signal peptide sequence portion, a single chain antibody fragment sequence portion, a hinge region sequence portion, a transmembrane domain sequence portion, and one or more intracellular domain sequence portions. Also disclosed herein are modified natural killer (NK) cells comprising the recombinant nucleic acid described above. Further disclosed herein are methods of treating a tumor in a subject by administering the modified NK cells.

Classes IPC  ?

• C07K 14/55 - IL-2
• A61K 40/15 - Lymphocytes NK [natural-killer]Lymphocytes NKT [natural-killer T]
• A61K 40/31 - Récepteurs antigéniques chimériques [CAR]
• A61K 40/42 - Antigènes associés au cancer
• A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
• C07K 14/705 - RécepteursAntigènes de surface cellulaireDéterminants de surface cellulaire
• C07K 14/725 - Récepteurs de lymphocytes-T
• C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
• C12N 5/0783 - Cellules TCellules NKProgéniteurs de cellules T ou NK
• C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales